Dohsa-hou for unexplained regression in Down syndrome in a 19-year-old man: A case report

Haruo Fujino, Aoi Moritsugu, Haruo Fujino, Aoi Moritsugu

Abstract

Unexplained regression in Down syndrome (URDS) has become a significant issue in clinical practice and research. This report illustrates the case of a patient with URDS treated with psychological treatment using Dohsa-hou, in addition to medication. Although psychological treatment may be helpful, monitoring potential risks of acute aggression is necessary.

Keywords: Down syndrome; behavioral symptoms; communication; interpersonal relations; psychosocial intervention.

Conflict of interest statement

The authors declare no competing interests.

© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Patient's total NPI score (symptom) and the caregiver's distress during the treatment. The period before and after the intervention is shown by a dotted line. NPI: Neuropsychiatric Inventory

References

    1. Akahoshi K, Matsuda H, Funahashi M, Hanaoka T, Suzuki Y. Acute neuropsychiatric disorders in adolescents and young adults with Down syndrome: Japanese case reports. Neuropsychiatr Dis Treat. 2012;8:339‐345.
    1. Jacobs J, Schwartz A, McDougle CJ, Skotko BG. Rapid clinical deterioration in an individual with Down syndrome. Am J Med Genet A. 2016;170(7):1899‐1902.
    1. Mircher C, Cieuta‐Walti C, Marey I, et al. Acute regression in young people with down syndrome. Brain Sci. 2017;7(6):57.
    1. Prasher V. Disintegrative syndrome in young adults with Down syndrome. Ir J Psychol Med. 2002;19(3):101‐102.
    1. Santoro SL, Cannon S, Capone G, et al. Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genet Med. 2020;22(4):767‐776.
    1. Jap SN, Ghaziuddin N. Catatonia among adolescents with Down syndrome: a review and 2 case reports. J ECT. 2011;27(4):334‐337.
    1. Japan Society of Pediatric Genetics . Diagnostic manual of regression of social and communication skills in Down syndrome. 2011. Available from:
    1. Cardinale KM, Bocharnikov A, Hart SJ, et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. Dev Med Child Neurol. 2019;61(7):847‐851.
    1. Ghaziuddin N, Nassiri A, Miles JH. Catatonia in Down syndrome; a treatable cause of regression. Neuropsychiatr Dis Treat. 2015;11:941‐949.
    1. Tamasaki A, Saito Y, Ueda R, et al. Effects of donepezil and serotonin reuptake inhibitor on acute regression during adolescence in Down syndrome. Brain Dev. 2016;38(1):113‐117.
    1. Fujino H. Psychological support for young adults with Down syndrome: dohsa‐hou program for maladaptive behaviors and internalizing problems. Front Psychol. 2017;8:1504.
    1. Tanaka S. A case study of the dohsa‐hou for adolescent with Down's syndrome having the problem behavior of intepersonal relations. Jpn J Rehabil Psychol. 1995;21:29‐37.
    1. Naruse G. The clinical Dohsa‐hou for cerebral palsied persons. Jpn J Rehabil Psychol. 1997;25:1‐8.
    1. Toya K. The dohsa method. Emot Behav Diffic. 2003;8(2):152‐163.
    1. Fujino H. Effects of Dohsa‐hou relaxation on body awareness and psychological distress. Jpn Psychol Res. 2012;54(4):388‐399.
    1. Kabir RS, Haramaki Y, Ki H, Ohno H. Self‐active relaxation therapy (SART) and self‐regulation: a comprehensive review and comparison of the Japanese body movement approach. Front Hum Neurosci. 2018;12:21.
    1. Naruse G. The clinical Dohsa‐hou as psychotherapy. Jpn J Rehabil Psychol. 1997;25(1):9‐16.
    1. Imura O, Chervenkova V. Introduction to Dohsa‐hou: An integrated Japanese body‐mind therapy: Osaka: Graduate School of Human Sciences. Osaka University: 2016.
    1. Abe K, Kabir RS, Haramaki Y. Referencing the body for mood state regulation: an examination of stress management using Dohsa‐hou as a primary prevention program for nurses. Environ Occup Health Pract. 2019;1(2):55‐60.
    1. Naruse G. Rinsho Dohsa Gaku Kiso [Foundation of Dohsa‐hou]. Gakuensha; 1995.
    1. Fujino H. Body awareness and mental health: a body psychotherapy case study. Body Mov Dance Psychother. 2016;11(4):249‐262.
    1. Kamikura Y, Shimizu R. The development Japanese body psychotherapy. Int Body Psychother J. 2021;20(1):124‐129.
    1. Cummings JL, Mega M, Gray K, Rosenberg‐Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308‐2314.
    1. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the neuropsychiatric inventory caregiver distress scale. J Am Geriatr Soc. 1998;46(2):210‐215.
    1. Matsumoto N, Ikeda M, Fukuhara R, et al. Validity and reliability of the Japanese version of the neuropsychiatric inventory caregiver distress scale (NPI D) and the neuropsychiatric inventory brief questionnaire form (NPI‐Q). No to Shinkei. 2006;58(9):785‐790.
    1. Dekker AD, Strydom A, Coppus AM, et al. Behavioural and psychological symptoms of dementia in Down syndrome: early indicators of clinical alzheimer's disease? Cortex. 2015;73:36‐61.
    1. Neil N, Amicarelli A, Anderson BM, Liesemer K. A meta‐analysis of single‐case research on applied behavior analytic interventions for people with down syndrome. Am J Intellect Dev Disabil. 2021;126(2):114‐141.
    1. Bowden CL, Grunze H, Mullen J, et al. A randomized, double‐blind, placebo‐controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66(1):111‐121.
    1. Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M. A double‐blind placebo‐controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry. 2000;57(7):649‐654.
    1. Ohlund L, Ott M, Oja S, et al. Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study. BMC Psychiatry. 2018;18(1):37.
    1. Ott M, Stegmayr B, Salander Renberg E, Werneke U. Lithium intoxication: Incidence, clinical course and renal function ‐ a population‐based retrospective cohort study. J Psychopharmacol. 2016;30(10):1008‐1019.
    1. Dawson M, Fletcher‐Watson S. When autism researchers disregard harms: a commentary. Autism. 2022;26(2):564‐566.
    1. Papaioannou D, Cooper C, Mooney C, Glover R, Coates E. Adverse event recording failed to reflect potential harms: a review of trial protocols of behavioral, lifestyle and psychological therapy interventions. J Clin Epidemiol. 2021;136:64‐76.
    1. Witt S, Kristensen K, Wiegand‐Grefe S, et al. Rare pediatric diseases and pathways to psychosocial care: a qualitative interview study with professional experts working with affected families in Germany. Orphanet J Rare Dis. 2021;16(1):497.
    1. Talic S, Shah S, Wild H, et al. Effectiveness of public health measures in reducing the incidence of covid‐19, SARS‐CoV‐2 transmission, and covid‐19 mortality: systematic review and meta‐analysis. BMJ. 2021;375:e068302.
    1. Brown JF, Brown MZ, Dibiasio P. Treating individuals with intellectual disabilities and challenging behaviors with adapted dialectical behavior therapy. J Ment Health Res Intellect Disabil. 2013;6(4):280‐303.
    1. Mathiassen B, Brondbo PH, Waterloo K, et al. IQ as a moderator of outcome in severity of children's mental health status after treatment in outpatient clinics. Child Adolesc Psychiatry Ment Health. 2012;6(1):22.
    1. Susanty D, Noel P, Sabeh MS, Jahoda A. Benefits and cultural adaptations of psychosocial interventions for parents and their children with intellectual disabilities in low‐and middle‐income countries: a systematic review. J Appl Res Intellect Disabil. 2021;34(2):421‐445.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever